Literature DB >> 29167546

Osteoporosis: Teriparatide preferable for fracture prevention.

Joanna Collison.   

Abstract

Entities:  

Year:  2017        PMID： 29167546     DOI： 10.1038/nrrheum.2017.194

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  1 in total

1.  Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.

Authors:  David L Kendler; Fernando Marin; Cristiano A F Zerbini; Luis A Russo; Susan L Greenspan; Vit Zikan; Alicia Bagur; Jorge Malouf-Sierra; Péter Lakatos; Astrid Fahrleitner-Pammer; Eric Lespessailles; Salvatore Minisola; Jean Jacques Body; Piet Geusens; Rüdiger Möricke; Pedro López-Romero
Journal:  Lancet       Date:  2017-11-09       Impact factor: 79.321
  1 in total
  4 in total

1.  MiR-21 nanocapsules promote early bone repair of osteoporotic fractures by stimulating the osteogenic differentiation of bone marrow mesenchymal stem cells.

Authors:  Xiaolei Sun; Xueping Li; Hongzhao Qi; Xin Hou; Jin Zhao; Xubo Yuan; Xinlong Ma
Journal:  J Orthop Translat       Date:  2020-05-19       Impact factor: 5.191

2.  Let-7i-5p functions as a putative osteogenic differentiation promoter by targeting CKIP-1.

Authors:  Yang Zhang; Wei Cheng; Biao Han; Yong Guo; Shuping Wei; Lu Yu; Xizheng Zhang
Journal:  Cytotechnology       Date:  2021-01-04       Impact factor: 2.058

3.  miR‑488 negatively regulates osteogenic differentiation of bone marrow mesenchymal stem cells induced by psoralen by targeting Runx2.

Authors:  Yongquan Huang; Qiuke Hou; Haitao Su; Dongfeng Chen; Yiwen Luo; Tao Jiang
Journal:  Mol Med Rep       Date:  2019-08-23       Impact factor: 2.952

4.  Effect of teriparatide on quality of life in patients with postmenopausal osteoporosis: a retrospective cohort study.

Authors:  Tiansong Yang; Chuwen Feng; Yuanyuan Qu; Qingyong Wang; Yan Yang; Bo Wang; Zhongren Sun; Shengyong Bao
Journal:  J Int Med Res       Date:  2019-10-10       Impact factor: 1.671
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.